Search results for abx831075

Briakinumab, Abbexa, abx831075

Briakinumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL12B, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. As of 2011 drug development for psoriasis has been discontinued in the U. S. and Europe. Briakinumab targets and neutralizes interleukin-12 and interleukin-23.